Related Experiment Video
Updated: Jun 22, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Fibrinogen gene polymorphism (Bbeta-148C/T) in Uygur patients with cerebral infarction
Xuebing Guo1, Danni Zhang, Xiaoning Zhang
1Department of Neurology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Objective:
To explore the frequency distribution of the fibrinogen gene polymorphism (Bbeta-148C/T) and its relationship with plasma fibrinogen (Fg) level in Uygur patients with cerebral infarction in Xinjiang.
Methods:
The frequency distribution of FgBbeta-148C/T was analysed by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in the Uygur cerebral infarction group (n=62) and the Uygur control group without cerebral infarction (n=64). Plasma fibrinogen levels were measured by the automatic coagulation analyser.
Results:
The frequency of the T allele in the cerebral infarction group was significantly higher than that of the control group (0.31 versus 0.19, p<0.05). The plasma fibrinogen level of the cerebral infarction group was also significantly higher than that of the control group (4.19 +/- 1.29 g/l versus 3.08 +/- 0.56 g/l, p<0.01). The plasma fibrinogen levels in both CT and TT genotype subgroups in patients with cerebral infarction were higher than those in the CC genotype subgroups (p<0.01). They were also higher than those in the CT and TT genotype subgroups within the control group (p<0.05).
Conclusion:
The fibrinogen gene polymorphism (Bbeta-148C/T) affects plasma fibrinogen concentration. T allele, alone or cooperating with other risk factors, increases the plasma fibrinogen level. Thus, the fibrinogen gene polymorphism (Bbeta-148C/T) may be related with cerebral infarction. T allele may be a risk factor for cerebral infarction by increasing the plasma fibrinogen level. The above conclusion is in accordance with similar studies on the Han nationality in China.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Hemorrhagic Stroke ll: Pathophysiology
Clot Retraction and Fibrinolysis